These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17987547)

  • 1. Potential utility of combination therapy with nateglinide and telmisartan for metabolic derangements in Zucker Fatty rats.
    Kajioka T; Miura K; Kitahara Y; Yamagishi S
    Horm Metab Res; 2007 Dec; 39(12):889-93. PubMed ID: 17987547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats.
    Miura K; Kitahara Y; Yamagishi S
    Horm Metab Res; 2010 Sep; 42(10):731-5. PubMed ID: 20625970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in zucker Fatty rats by suppressing advanced glycation end product receptor axis.
    Miura K; Kitahara Y; Kajioka T; Takeuchi M; Yamagishi S
    Horm Metab Res; 2011 Mar; 43(3):226-8. PubMed ID: 20972939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.
    Mine T; Miura K; Kitahara Y; Okano A; Kawamori R
    Biol Pharm Bull; 2002 Nov; 25(11):1412-6. PubMed ID: 12419950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nateglinide].
    Notoya Y; Kikuchi M
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
    [No Abstract]   [Full Text] [Related]  

  • 6. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
    Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
    Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
    Fonseca V; Grunberger G; Gupta S; Shen S; Foley JE
    Diabetes Care; 2003 Jun; 26(6):1685-90. PubMed ID: 12766094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
    Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
    J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action.
    Zhao ZQ; Luo R; Li LY; Tian FS; Zheng XL; Xiong HL; Sun LT
    Can J Diabetes; 2013 Jun; 37(3):156-68. PubMed ID: 24070838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes.
    Kitahara Y; Miura K; Takesue K; Mine T; Wada R; Uchida Y; Ito S; Yagihashi S
    Metabolism; 2002 Nov; 51(11):1452-7. PubMed ID: 12404197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of type 2 diabetes].
    Ikenoue T; Kondo N
    Nihon Yakurigaku Zasshi; 2000 Sep; 116(3):171-80. PubMed ID: 11031747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of nateglinide in the management of patients with type 2 diabetes.
    Tentolouris N; Voulgari C; Katsilambros N
    Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nateglinide prevents fatty liver through up-regulation of lipid oxidation pathway in Goto-Kakizaki rats on a high-fat diet.
    Mine T; Miura K; Kajioka T; Kitahara Y
    Metabolism; 2008 Jan; 57(1):140-8. PubMed ID: 18078871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats.
    Miesel A; Müller-Fielitz H; Jöhren O; Vogt FM; Raasch W
    Br J Pharmacol; 2012 Apr; 165(8):2721-35. PubMed ID: 22014027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
    Saloranta C; Hershon K; Ball M; Dickinson S; Holmes D
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4171-6. PubMed ID: 12213867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of nateglinide on insulin resistance in type 2 diabetes.
    Hazama Y; Matsuhisa M; Ohtoshi K; Gorogawa S; Kato K; Kawamori D; Yoshiuchi K; Nakamura Y; Shiraiwa T; Kaneto H; Yamasaki Y; Hori M
    Diabetes Res Clin Pract; 2006 Mar; 71(3):251-5. PubMed ID: 16214255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome.
    Kagota S; Tada Y; Nejime N; Nakamura K; Kunitomo M; Shinozuka K
    Can J Physiol Pharmacol; 2011 May; 89(5):355-64. PubMed ID: 21619437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.